Hansa Biopharma (Q3 Update): Europe Below Expectations, but the US Will Drive Value - Redeye

Redeye comments on Hansa Biopharma's Q3 report. Product sales declined sequentially in Europe. The pause in the Eurotransplant programme is impacting sales. The positive results from the US ConfideS open the way for a US sales launch in kidney transplants, pending approval. The US market will be the most significant value driver in the mid- to long-term. With a pro-forma cash position of SEK888m, the runway is into 2027.

Länk till analysen i sin helhet: https://www.redeye.se/research/1134465/hansa-biopharma-q3-update-europe-below-expectations-but-the-us-will-drive-value?utm_source=finwire&utm_medium=RSS